Embargoed: 0700hrs, 6 December 2011
Akers Biosciences, Inc.("ABI" or the "Company")
Launch of revolutionary PIFA PLUSS PF4 Rapid Assay wholeblood technology
Akers Biosciences, Inc. (AIM:AKR), a leading designer and
manufacturer of rapid diagnostic screening and testing
products, is pleased to announce that its patentedblood cell
separator technology (the "Technology") will be integrated
into the Company's PIFA Rapid Assay platformand launched into
market in January 2012.
The Technology enables the immediate separation of serum (the
liquid component of blood) from a patient's finger stick or
venous whole blood sample and then introduces the extracted
specimen into a rapid assay device to providea real-time
result. In addition, whole blood treated with certain
anticoagulants, commonly used in some coagulation
laboratories, will now be compatible with the Company's PIFA
Rapid Assay platform.
The Technology, which fulfills all of the requirements of the
FDA for marketability,is designed to be adaptable and can
also be applied to other diagnostic testing
methodologies.
This enhancement drastically improves assay turn-around-time
which is critical not only to point-of-care ("POC")
screening, but to all in vitro diagnostic testing overseen by
the laboratory. In the Company's interim statement of
7 September 2011, the product was referred to as "PIFA POC";
it will now be branded under the trade name
PIFA PLUSS to represent the addition of our Serum Separation
technology into the PIFA platform.
The initial introduction of this product line extension will
expand the Company's franchise in the Heparin-Induced
Thrombocytopenia ("HIT") rapid testing market. The PIFA PLUSS
PF4 Rapid Assay will be uniquely positioned as the only whole
blood, disposable screening device for the rapid detection of
antibodies which are a major determinant in the pathogenesis
of HIT, a life-and limb-threatening complication of treatment
with the blood- thinner Heparin.
The Company plans to apply the Technology to many of itsother
diagnostic products, including its infectious disease suite
of rapid assays, which includes diagnosis of Chlamydia and
Malaria. In the USA, the PIFA PLUSS PF4 Rapid Assay will be
sold to end-users exclusively by ABI's direct sales force;
the Company is actively seeking partners for non-USA
distribution.
"With an industry shift towards expedited test results in the
clinical laboratory and at the point-of-care, the forthcoming
launch of our revolutionary blood cell separator technology
within our PIFA platform represents a breakthrough in
diagnostic testing.
PIFA PLUSS narrows the entire test procedure, inclusive of
sample preparation, to a timeline measured in minutes, versus
traditional more labour-intensive and slower methods which
can involve samples being sent away to external laboratories.
The product further demonstrates our continued dedication to
technology enhancement and to delivering clinically-relevant
information for laboratorians, and the physicians whom they
support, in a timely and cost-efficient manner.
In addition to the anticipated value this Technology will
bring to ABI's portfolio, the adaptability of the
Technology may lead to partnerships with other diagnostic
firms for use on their own platforms."
Thomas A. Nicolette, President and CEO
Dr. Raymond F. Akers, Jr., Executive Chairman
Tel. +1 856 848 8698
Noelle Greenaway
Daniel Stewart & Company plc (Nominated Adviser and Broker)
Tel. +44(0)20 7776 6550
Ben Simons
M: Communications
Tel. +44(0)20 7920 2340
Akers Biosciences develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributorsto maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com
distribué par | Ce noodl a été diffusé par Akers Biosciences Inc. et initialement mise en ligne sur le site http://www.akersbiosciences.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2011-12-06 13:25:04 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Launch of PIFA PLUSS PF4 Rapid Assay |